1. Introduction {#sec1-nutrients-11-01467}
===============

Ischemic stroke is characterized by an episode of neurological dysfunction attributed to cerebral infarction in the perfusion territory of an stenosed or occluded artery \[[@B1-nutrients-11-01467]\]. Ischemic stroke is a major cause of death and disability worldwide, but some studies have indicated that adherence to a healthy diet and lifestyle may be of importance for reduction of ischemic stroke risk \[[@B2-nutrients-11-01467],[@B3-nutrients-11-01467]\].

An important part of a healthy diet is believed to be an increased intake of polyunsaturated fatty acids (PUFAs). PUFAs are organic acids that naturally contains two or more double bonds in their carbon chain and are named according to the number, configuration and position of these double bonds \[[@B4-nutrients-11-01467]\]. PUFAs are upon ingestion incorporated into cell membranes and storage pools, utilised in energy production or converted into longer and more unsaturated fatty acids, which may give rise to biological compounds that may affect a variety of biological processes \[[@B5-nutrients-11-01467]\]. PUFAs have traditionally been divided into n-3 PUFAs and n-6 PUFAs and these two families each consist of fatty acids with varying carbon chain length and degree of unsaturation, which are important for their physiological and biological properties \[[@B4-nutrients-11-01467]\]. The major n-3 PUFAs include the short-chain plant-derived n-3 PUFA, alpha-linolenic acid (ALA, 18:3n-3), and the longer-chain marine n-3 PUFAs eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3) and docosahexaenoic acid (DHA, 22:6n-3).

The major dietary n-6 PUFA is linoleic acid (LA, 18:2n-6) and together with ALA are the PUFAs consumed in largest amounts. The typical intake of LA in Western populations range between 10 to 17 g/d, while the average intake of ALA varies between 0.5 to 2.3 g/d \[[@B5-nutrients-11-01467],[@B6-nutrients-11-01467],[@B7-nutrients-11-01467]\]. The major sources of LA include plant oils, meat and eggs \[[@B6-nutrients-11-01467]\], while ALA is found in large amounts in some plant oils, but can be also be found in walnuts, green vegetables, whole-grain cereals, margarines, dairy products and meat \[[@B8-nutrients-11-01467],[@B9-nutrients-11-01467],[@B10-nutrients-11-01467]\]. LA and ALA are precursors for further desaturation and elongation products along a shared metabolic pathway. LA can thus be converted into arachidonic acid (AA, 20:4n-6), while ALA can be converted into LC n-3 PUFAs, however, the conversion efficiency seems to be limited in humans and influenced by gender, genetics and intake of other fatty acids \[[@B5-nutrients-11-01467],[@B11-nutrients-11-01467]\]. The LC n-3 PUFAs can be acquired from seafood and especially fatty fish and their biological effects has been extensively studied over the recent decades since Dyerberg and colleagues hypothesized that LC n-3 PUFAs in particular EPA were protective against atherothrombosis \[[@B12-nutrients-11-01467],[@B13-nutrients-11-01467],[@B14-nutrients-11-01467]\].

LC n-3 PUFAs has been ascribed several effects that might be beneficial in the prevention of ischemic stroke including lowering of triglycerides, inflammation, blood pressure and platelet aggregability, and improved endothelial function and atherosclerotic plaque stability, which likely are mediated by a combination of mechanisms \[[@B4-nutrients-11-01467],[@B14-nutrients-11-01467],[@B15-nutrients-11-01467],[@B16-nutrients-11-01467],[@B17-nutrients-11-01467]\]. On the other hand the biological effects of other PUFAs have been less studied, but few studies have suggested that ALA might be associated with anti-inflammatory and anti-atherosclerotic properties \[[@B18-nutrients-11-01467]\]. Whether these suggested effects is mediated by ALA per se or can be attributed to its role as a precursor for LC n-3 PUFAs, however, remains unclear. LA has been reported to be associated with lowering of low-density lipoprotein (LDL) cholesterol, blood pressure and insulin resistance \[[@B19-nutrients-11-01467]\], all important for atherosclerotic risk. Concerns have, however, been raised that LA could confer a higher risk of vascular disease due to its role as a precursor of AA that gives rise to eicosanoids considered pro-inflammatory and pro-thrombotic including formation of proinflammatory leukotriene B4 from leukocytes and proaggregatory and vasoconstrictive thromboxane A2 \[[@B4-nutrients-11-01467]\]. However, stable isotope studies and clinical trials have indicated that high intakes of LA do not seem to significantly increase tissue levels of AA or increased production of inflammatory mediators \[[@B20-nutrients-11-01467]\]. Indeed, there is actually some indications that LA might possess anti-inflammatory effects \[[@B20-nutrients-11-01467],[@B21-nutrients-11-01467]\].

Several studies have suggested that LC n-3 PUFAs and LA may be associated with a lower risk of coronary heart disease (CHD) \[[@B4-nutrients-11-01467],[@B22-nutrients-11-01467],[@B23-nutrients-11-01467],[@B24-nutrients-11-01467]\]. Although, CHD and ischemic stroke may share pathophysiological similarities, less is known about the role of PUFAs in relation to risk of ischemic stroke and previous studies have not yielded consistent results.

The objective of this paper was to summarize the main findings from previous follow-up studies investigating associations between intake or biomarkers of exposure of the major PUFAs (ALA, LC n-3 PUFAs, and LA) and ischemic stroke.

2. ALA and Ischemic Stroke {#sec2-nutrients-11-01467}
==========================

Few studies have investigated the association between ALA intake and ischemic stroke \[[@B25-nutrients-11-01467],[@B26-nutrients-11-01467],[@B27-nutrients-11-01467],[@B28-nutrients-11-01467],[@B29-nutrients-11-01467]\] ([Table 1](#nutrients-11-01467-t001){ref-type="table"}). In the Monitoring Project on Risk Factors for Chronic Diseases Study (MORGEN Study), dietary intake of ALA was inversely associated with the rate of total ischemic stroke among Dutch men and women \[[@B25-nutrients-11-01467]\]. In the Cardiovascular Health Study (CHS), indications of a lower rate of total ischemic stroke were observed when comparing the highest quintile of ALA intake with the lowest, but no consistent pattern of association was observed across quintiles of ALA in this cohort of US men and women \[[@B26-nutrients-11-01467]\]. Further, no clear association was observed between ALA intake and the rate of total ischemic stroke among women enrolled into the Women's Health Study \[[@B27-nutrients-11-01467]\] or the Swedish Mammography Cohort \[[@B28-nutrients-11-01467]\] and among men and women enrolled into the Diet, Cancer and Health (DCH) cohort \[[@B29-nutrients-11-01467]\]. Limited knowledge is available regarding the associations between ALA intake and the risk of ischemic stroke subtypes but no appreciable pattern of associations were observed between intake of ALA and the rate of ischemic stroke subtypes caused by large artery atherosclerosis, small vessel-occlusion or cardioembolism in the DCH cohort \[[@B29-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}).

The findings from previous follow-up and nested-case control studies using biomarkers of ALA to investigate associations with ischemic stroke have not been conclusive \[[@B26-nutrients-11-01467],[@B31-nutrients-11-01467],[@B32-nutrients-11-01467],[@B33-nutrients-11-01467],[@B38-nutrients-11-01467],[@B39-nutrients-11-01467],[@B40-nutrients-11-01467]\] ([Table 3](#nutrients-11-01467-t003){ref-type="table"}). In a large case-cohort study based on data from the DCH cohort we reported indications of a U-shaped pattern of association between adipose tissue content of ALA and the rate of total ischemic stroke although not statistically significant \[[@B33-nutrients-11-01467]\]. A follow-up study based on the Finish Kuopio Ischaemic Heart Disease Risk Factors (KIHD) study also reported indications of a U-shaped pattern of association between quartiles of ALA content in serum and total ischemic stroke, while a nested case-control study reported a modest non-significant inverse association between ALA in serum and total ischemic stroke \[[@B32-nutrients-11-01467],[@B40-nutrients-11-01467]\]. In contrast, several other biomarker studies did not find ALA content in serum, plasma phospholipids or cholesterol esters associated with the risk of total ischemic stroke \[[@B26-nutrients-11-01467],[@B31-nutrients-11-01467],[@B38-nutrients-11-01467],[@B39-nutrients-11-01467]\].

Limited data are available on biomarkers of ALA and ischemic stroke subtypes ([Table 2](#nutrients-11-01467-t002){ref-type="table"}). However, data from the DCH cohort suggested a statistically significant U-shaped association between ALA content in adipose tissue and the rate of ischemic stroke due to large artery atherosclerosis with the lowest rate observed around the median content of ALA in adipose tissue \[[@B33-nutrients-11-01467]\]. In contrast, a positive statistically non-significant association was observed between ALA content in adipose tissue and the rate of ischemic stroke due to cardioembolism, whereas no appreciable association was found between ALA in adipose tissue and ischemic stroke due to small-vessel occlusion \[[@B33-nutrients-11-01467]\].

In summary, previous studies evaluating either intake of ALA or content of ALA in blood components or adipose tissue have shown conflicting results, but most studies does not support that ALA exposure is inversely associated with ischemic stroke risk.

3. Marine LC n-3 PUFAs and Ischemic Stroke {#sec3-nutrients-11-01467}
==========================================

Several studies have investigated the association between intake of LC n-3 PUFAs and total ischemic stroke \[[@B27-nutrients-11-01467],[@B28-nutrients-11-01467],[@B30-nutrients-11-01467],[@B35-nutrients-11-01467],[@B41-nutrients-11-01467],[@B42-nutrients-11-01467],[@B43-nutrients-11-01467],[@B44-nutrients-11-01467],[@B45-nutrients-11-01467],[@B46-nutrients-11-01467]\] ([Table 4](#nutrients-11-01467-t004){ref-type="table"}) and has recently been reviewed \[[@B47-nutrients-11-01467]\]. In brief, findings from the Nurses' Health Study (NHS) indicated a statistically non-significant inverse pattern of associations between EPA+DHA intake and the rate of total ischemic stroke \[[@B30-nutrients-11-01467]\]. Analyses of ischemic stroke subtypes showed an inverse pattern of associations between EPA+DHA intake and lacunar infarctions, while no clear associations were observed for large artery occlusive infarctions \[[@B30-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}). Lower rates of total ischemic stroke across quintiles of EPA+DHA intake were observed in the Swedish Mammography cohort \[[@B28-nutrients-11-01467]\] and in the Health Professionals Follow Study (HPFS) although results were not statistically significant in the latter when comparing the highest quintile of intake with the lowest \[[@B41-nutrients-11-01467]\]. In the MORGEN study, gender-specific analyses indicated lower rates of total ischemic stroke in subjects with a high EPA+DHA intake, but the confidence intervals were wide and the point estimates were not statistically significant \[[@B42-nutrients-11-01467]\]. A recent study from our groups by Venø et al. \[[@B35-nutrients-11-01467]\] investigated associations between dietary intake of total marine LC n-3 PUFAs and of individual marine n-3 PUFAs and the rate of total ischemic stroke and ischemic stroke subtypes using data from the DCH cohort. In dietary analyses, no appreciable associations were observed between intake of total and individual n-3 PUFAs, EPA or DHA and the rate of total ischemic stroke \[[@B35-nutrients-11-01467]\]. Also, in five other follow-up studies, no consistent pattern of associations between EPA+DHA intake and rate of total ischemic strokes were reported \[[@B27-nutrients-11-01467],[@B43-nutrients-11-01467],[@B44-nutrients-11-01467],[@B45-nutrients-11-01467],[@B46-nutrients-11-01467]\]. However, in the study by Venø et al. a high intake of total n-3 PUFAs, EPA and DHA was statistically significantly associated with lower rates of ischemic stroke due to large artery atherosclerosis when comparing the highest quartile of intake with the lowest \[[@B35-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}). In contrast, indications of higher rates of ischemic stroke due to cardioembolism were observed with intake of LC n-3 PUFAs, whereas no consistent pattern of association was observed between LC n-3 PUFAs and the rate of ischemic stroke due small-vessel occlusions \[[@B35-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}).

Some biomarker studies have investigated the associations between levels of LC n-3 PUFAs in blood compartments or adipose tissue and the risk of ischemic stroke \[[@B31-nutrients-11-01467],[@B32-nutrients-11-01467],[@B34-nutrients-11-01467],[@B35-nutrients-11-01467],[@B38-nutrients-11-01467],[@B39-nutrients-11-01467],[@B40-nutrients-11-01467],[@B48-nutrients-11-01467]\] ([Table 5](#nutrients-11-01467-t005){ref-type="table"}). Thus, a the content of EPA, DPA and DHA in plasma phospholipids was analysed in relation to ischemic stroke and its subtypes using pooled data from the CHS, NHS and HPFS \[[@B34-nutrients-11-01467]\]. Lower rates of total ischemic stroke was observed when comparing the highest quintile of content of DPA and DHA with the lowest, respectively, while no appreciable association was found for EPA \[[@B34-nutrients-11-01467]\]. However, the associations seemed to depend on the ischemic stroke subtype in question ([Table 2](#nutrients-11-01467-t002){ref-type="table"}). In analyses of ischemic stroke subtypes, DHA was associated with the rate of atherothrombotic strokes (large artery and small-vessel infarctions), whereas no association was found for EPA and DPA. However, DPA was associated with lower rates of cardioembolic strokes, whereas no associations were observed between EPA or DHA and the rate of cardioembolic stroke \[[@B34-nutrients-11-01467]\]. Few other studies have supported that circulating biomarkers of LC n-3 PUFAs might be associated with a lower risk of ischemic stroke although results have not been consistent \[[@B31-nutrients-11-01467],[@B32-nutrients-11-01467],[@B38-nutrients-11-01467],[@B40-nutrients-11-01467],[@B48-nutrients-11-01467]\] ([Table 5](#nutrients-11-01467-t005){ref-type="table"}).

The associations between adipose tissue content of LC n-3 PUFAs and the risk of ischemic stroke and ischemic stroke subtypes were investigated based on data from the DCH cohort and no appreciable association was observed between total adipose tissue of LC n-3 PUFAs and the rate of total ischemic stroke \[[@B35-nutrients-11-01467]\]. However, the EPA content in adipose tissue was inversely associated with the rate of total ischemic stroke when comparing the highest with the lowest quintile \[[@B35-nutrients-11-01467]\]. In contrast, adipose tissue content of DPA seemed to be associated with a higher rate of total ischemic stroke, whereas no association was found for DHA \[[@B35-nutrients-11-01467]\]. In analyses of ischemic stroke subtypes, the content of EPA in adipose tissue was inversely associated with the rate of ischemic stroke due to large artery atherosclerosis and small-vessel occlusions, while a higher rate of ischemic stroke due to cardioembolism was noted when comparing the highest quartile with the lowest although not statistically significant \[[@B35-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}). Adipose tissue content of DPA and DHA was associated with higher rates of ischemic stroke caused by cardioembolism whereas no consistent pattern of association was found for ischemic stroke caused by large artery atherosclerosis or small-vessel occlusions \[[@B35-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}).

In summary, several large prospective studies evaluating EPA and/or DHA intake or their content in blood components or adipose tissue have suggested an inverse association although results have not been consistent. The associations between LC n-3 PUFAs and ischemic stroke subtypes may differ with the most beneficial results observed in subjects with strokes of atherosclerotic etiology.

4. LA and Ischemic Stroke {#sec4-nutrients-11-01467}
=========================

Studies of the association between dietary intake of LA and the rate of ischemic stroke are sparse ([Table 6](#nutrients-11-01467-t006){ref-type="table"}). In analyses based on data from the Swedish Mammography Cohort, no association was observed between intake of LA+AA and the rate of total ischemic stroke \[[@B28-nutrients-11-01467]\]. Also, no clear association was observed between LA+AA intake and the rate of total ischemic stroke in another Swedish cohort \[[@B45-nutrients-11-01467]\]. However, the intake of LA and AA was not analysed separately and the macronutrient(s) to be replaced for n-6 PUFAs was not specified in these studies. In contrast to n-3 PUFAs, LA constitute a significant proportion of total energy intake and a higher intake of LA must necessarily be accompanied by a lower intake of other macronutrients in an isocaloric setting. In a follow-up study using statistical substitution models we therefore investigated the risk of total ischemic stroke and ischemic stroke subtypes with a 5% higher intake of LA and a concomitant lower intake from saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs) or glycemic carbohydrates using data from the DCH cohort \[[@B36-nutrients-11-01467]\]. This study suggested that replacing MUFAs or glycemic carbohydrates with LA might be associated with a lower risk of total ischemic stroke although not statistically significantly \[[@B36-nutrients-11-01467]\]. Further, in analyses of ischemic stroke subtypes, replacement of SFA with LA indicated a lower rate of ischemic stroke due to large artery atherosclerosis and replacement of glycemic carbohydrates with LA indicated a lower rate of ischemic stroke due to small-vessel occlusions, although the observed associations were not statistically significant \[[@B36-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}). A statistically significant lower rate of ischemic stroke due to small-vessel occlusions was observed when LA replaced MUFAs \[[@B36-nutrients-11-01467]\] ([Table 2](#nutrients-11-01467-t002){ref-type="table"}).

Several prospective biomarker studies have supported that circulating or adipose tissue content of LA may be associated with a lower risk of ischemic stroke although results have not been consistent \[[@B23-nutrients-11-01467],[@B31-nutrients-11-01467],[@B32-nutrients-11-01467],[@B37-nutrients-11-01467],[@B38-nutrients-11-01467],[@B39-nutrients-11-01467],[@B40-nutrients-11-01467],[@B49-nutrients-11-01467]\] ([Table 7](#nutrients-11-01467-t007){ref-type="table"}). A previous study by Iso et al. suggested a lower odds of total ischemic stroke and lacunar infarctions per 1 SD increase in LA content in serum \[[@B31-nutrients-11-01467]\]. Also, in analyses based on data from the ARIC Study, a statistically significant inverse association between LA content in plasma cholesterol esters and the rate of total ischemic stroke and indications of an inverse association was observed between LA content in plasma phospholipids and the rate of total ischemic stroke \[[@B39-nutrients-11-01467]\]. Also, several other studies have indicated a lower risk of total ischemic stroke with the content of LA in serum, plasma phospholipids and cholesterol esters, but these findings were not statistically significant and not entirely consistent \[[@B32-nutrients-11-01467],[@B38-nutrients-11-01467],[@B40-nutrients-11-01467],[@B49-nutrients-11-01467]\]. However, a large case-cohort study based on data from the DCH study found a dose-dependent inverse association between adipose tissue content of LA and the rate of total ischemic stroke \[[@B37-nutrients-11-01467]\]. In analyses of ischemic stroke subtypes, adipose tissue content of LA was inversely associated with the rate of ischemic stroke due to large artery atherosclerosis and indications of lower rates of ischemic stroke due to small-vessel occlusions was observed, whereas no clear association was found between LA in adipose and the rate of ischemic stroke due to cardioembolism \[[@B37-nutrients-11-01467]\]. Recently, a harmonized individual-level analysis based on prospective data from the Fatty Acid and Outcome Research Consortium (FORCE) found an overall lower rate of total ischemic stroke with higher levels of LA in blood compartments and adipose tissue in analyses including 3705 incident ischemic stroke cases \[[@B23-nutrients-11-01467]\].

In summary, limited evidence regarding LA intake and ischemic stroke exist, but LA intake might be associated with a lower risk of total ischemic stroke although the association may depend on macronutrient used to replace LA and the ischemic stroke subtype in question. Several biomarker studies have supported that a high content of LA in blood components or adipose tissue may be associated with a lower risk of total ischemic stroke.

5. Discussion {#sec5-nutrients-11-01467}
=============

Several prospective follow-up studies have suggested that LC n-3 PUFAs perhaps in particular EPA and DHA may be associated with a lower risk of total ischemic stroke although results have not been consistent. A few studies have suggested that the associations between individual LC n-3 PUFAs may differ amongst subtypes of ischemic stroke with the most beneficial findings observed in ischemic strokes of presumed atherosclerotic origin. Regarding the role of ALA for development of ischemic strokes, most prospective studies have not supported that ALA may be appreciably associated with a lower risk of ischemic stroke. The associations between LA and ischemic stroke have been less studied than the role of n-3 PUFAs, but some biomarker studies have supported that LA might be associated with a lower risk of ischemic stroke. Limited evidence exist regarding LA intake and ischemic stroke, but the association may depend on the macronutrient used to replace LA.

Biomarkers of PUFA exposure may represent useful complementary measures of exposure to investigate the associations with chronic diseases such as ischemic stroke \[[@B50-nutrients-11-01467]\]. Dietary studies using estimated PUFA intakes as exposure are limited by measurement error, which may result in loss of statistical power and attenuation of associations toward null. In contrast, the content of PUFAs in blood components or adipose tissue can be assessed more precise and are considered objective biomarkers of exposure \[[@B50-nutrients-11-01467],[@B51-nutrients-11-01467]\]. Long-term measures of exposure is likely to be of greater etiological relevance in the development of ischemic stroke compared to short-term measures of exposure. Adipose tissue is considered the gold standard due to a slow turnover time possibly reflecting intake of PUFAs during the previous 1--2 years, whereas shorter-term biomarkers such as PUFA content in blood components may represent the exposure up to few months. However, the content of PUFAs in blood components or adipose tissue reflects both intake and metabolism \[[@B50-nutrients-11-01467]\]. Also, direct comparison of measures of associations obtained in previous biomarker of PUFAs from different population should be done with caution because differences in PUFA content in human tissue may be largely influenced by differences in the underlying dietary pattern \[[@B50-nutrients-11-01467],[@B51-nutrients-11-01467]\].

Finally, ischemic stroke is a heterogeneous condition and it is likely that the biological effects of individual LC n-3 PUFAs and LA may differ across subtypes of ischemic stroke of different etiology. Ischemic stroke due to large artery atherosclerosis is considered to be of atherosclerotic origin, whereas ischemic stroke due to small-vessel occlusion may develop as a result of atherosclerosis or lipohyalinosis affecting the smaller penetrating arteries in the brain \[[@B52-nutrients-11-01467],[@B53-nutrients-11-01467]\]. In contrast, ischemic cardio-embolic strokes are mainly caused by emboli arising from the heart due to arrhythmias, particularly atrial fibrillation or flutter. Furthermore, ischemic stroke may in rare cases develop as a result of nonatherosclerotic vasculopathies or prothrombotic disorders. Thus, these rather distinct potential causes of ischemic stroke underline that separate analyses of ischemic stroke subtypes may contribute with a better understanding of the underlying biology of exposure to PUFAs. Recent results based on data from the DCH cohort \[[@B35-nutrients-11-01467]\] and the pooled analyses by Saber et al. \[[@B34-nutrients-11-01467]\] indicated that the associations between individual LC n-3 PUFAs and ischemic stroke subtypes may differ. Interestingly, results from the DCH cohort indicated stronger associations for EPA and LA on ischemic stroke due to large artery atherosclerosis than for ischemic stroke due to small-vessel occlusion. This might indicate that potential anti-atherosclerotic properties of marine n-3 PUFAs may be of importance. Anti-atherosclerotic properties of LC n-3 PUFAs may include lowering of triglycerides and perhaps also of atherogenic small-dense LDL particles, a reduction in inflammation and blood pressure, while LA might inhibit the atherosclerotic process by lowering of LDL-cholesterol and blood pressure. EPA seemed to be stronger associated ischemic stroke due to large artery atherosclerosis than DHA in the DCH cohort, but whether these differences can be attributed to different biological effects remain unclear, but is not unlikely as many data support that a major effect of DHA on heart disease may be an antiarrhythmic effect.

In addition, the associations may depend on the macronutrients used to replace PUFAs and such substitution aspects together---with focus on dietary patterns---represent interesting areas for future research.
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nutrients-11-01467-t001_Table 1

###### 

Characteristics of observational follow-up studies investigating intake of alpha-linolenic acid (ALA) and total ischemic stroke.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and Study                                     Study Population and Country               Sex   No. of Participants   Baseline Age (yrs)   Exposure Assessment   Intake (g/d)    No. of Cases   Follow-up (yrs)   Hazard Ratios\           Variables Controlled for
                                                                                                                                                                                                                          (95% CI)                 
  ---------------------------------------------------- ------------------------------------------ ----- --------------------- -------------------- --------------------- --------------- -------------- ----------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  De Goede et al. 2011 \[[@B25-nutrients-11-01467]\]   The MORGEN Study cohort; The Netherlands   M+W   19,896                20--65               FFQ                   Q1: 1.0\        144            10.5              Q2: 0.63 (0.39; 1.02)\   Age; sex; BMI; total energy intake; cigarette smoking; educational level; parental history of MI; alcohol.
                                                                                                                                                                         Q3: 1.3\                                         Q3: 0.45 (0.26; 0.77)\   
                                                                                                                                                                         Q5: 1.9                                          Q4: 0.55 (0.33; 0.92)\   
                                                                                                                                                                                                                          Q5: 0.70 (0.43; 1.12)    

  Larsson et al. 2012 \[[@B28-nutrients-11-01467]\]    The Swedish Mammography Cohort; Sweden     W     34,670                49--83               FFQ                   Q1: 0.9\        1310           10.4              Q2: 0.99 (0.83; 1.17)\   Age; smoking status and pack-years of smoking; education; BMI; physical activity; hypertension; diabetes; aspirin; family history of MI; intakes of alcohol, protein, fiber and cholesterol.
                                                                                                                                                                         Q3: 1.1\                                         Q3: 1.03 (0.86; 1.22)\   
                                                                                                                                                                         Q5: 1.5                                          Q4: 1.00 (0.84; 1.19)\   
                                                                                                                                                                                                                          Q5: 1.11 (0.93; 1.32)    

  Fretts et al. 2014 \[[@B26-nutrients-11-01467]\]     The CHS cohort; United States              M+W   2583                  ≥65                  FFQ                   Q1: 1.3% ^1^\   278            9.6 ^2^           Q2: 0.89 (0.61; 1.30)\   Age; sex; total energy intake; race; enrollment site; education; smoking status; diabetes; BMI; waist circumference; physical activity; alcohol; treated hypertension.
                                                                                                                                                                         Q3: 1.8% ^1^\                                    Q3: 0.84 (0.58; 1.22)\   
                                                                                                                                                                         Q5: 2.4% ^1^                                     Q4: 1.08 (0.75; 1.54)\   
                                                                                                                                                                                                                          Q5: 0.70 (0.47; 1.04)    

  Rhee et al. 2017 \[[@B27-nutrients-11-01467]\]       The WHS cohort; United States              W     38,392                ≥45                  FFQ                   Q1: 0.7% ^3^\   807            18.2 ^2^          Q2: 0.89 (0.71; 1.13)\   Age; randomized treatment assignment; BMI; smoking; alcohol; physical activity; oral contraceptive use; HRT; multivitamins; total energy intake; family history of MI; hypertension; high cholesterol; diabetes.
                                                                                                                                                                         Q3: 1.0% ^3^\                                    Q3: 0.89 (0.71; 1.12)\   
                                                                                                                                                                         Q5: 1.4% ^3^                                     Q4: 1.05 (0.84; 1.30)\   
                                                                                                                                                                                                                          Q5: 1.02 (0.82; 1.27)    

  Bork et al. 2018 \[[@B29-nutrients-11-01467]\]       The DCH cohort; Denmark                    M+W   55,018                50--65               FFQ                   Q1: 1.2\        1859           13.5              Q2: 1.03 (0.87; 1.21)\   Age; gender; length of schooling; smoking; physical activity; waist circumference adjusted for BMI; alcohol.
                                                                                                                                                                         Q3: 1.8\                                         Q3: 1.12 (0.95; 1.31)\   
                                                                                                                                                                         Q5: 2.6                                          Q4: 1.03 (0.87; 1.22)\   
                                                                                                                                                                                                                          Q5: 1.10 (0.93; 1.31)    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: MORGEN, The Monitoring Project on Risk Factors for Chronic Diseases Study; M, men; W, Women; FFQ, Food Frequency Questionnaire; Q, Quintile; CI, Confidence interval; BMI, Body mass index; MI, Myocardial infarction; CHS, Cardiovascular Health Study; WHS, Women's Health Study; HRT, Hormone replacement therapy; DCH, Diet, Cancer and Health. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest quintile of intake was used as reference. ^1^ Percentage of total fatty acids; ^2^ Follow-up time was calculated as person-years of follow-up divided by the total number of participants; ^3^ Percentage of total energy intake.

nutrients-11-01467-t002_Table 2

###### 

Measures of association obtained in observational follow-up and nested case-control studies investigating intake or biomarkers of major PUFAs in relation to ischemic stroke subtypes.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and Exposures of Interest                     Large Artery Occlusive Infarctions                      Small-Vessel and Lacunar Infarctions                    Cardio-Embolic Infarctions
  ---------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  Iso et al. 2001 \[[@B30-nutrients-11-01467]\]                                                                                                                        

  No. cases                                            88                                                      142                                                     

  EPA+DHA intake                                       HR Q2-5 vs. Q1:\                                        HR Q2-5 vs. Q1:\                                        
                                                       Q2: 0.56 (0.28; 1.10)\                                  Q2: 0.89 (0.55; 1.43)\                                  
                                                       Q3: 0.50 (0.25; 1.02)\                                  Q3: 0.59 (0.34; 1.00)\                                  
                                                       Q4: 0.96 (0.51; 1.81)\                                  Q4: 0.67 (0.39; 1.14)\                                  
                                                       Q5: 1.09 (0.52; 2.29)                                   Q5: 0.37 (0.19; 0.73)                                   

  Iso et al. 2002 \[[@B31-nutrients-11-01467]\]                                                                                                                        

  No. of cases                                         19                                                      95                                                      8

  ALA in serum                                         OR: 0.82 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 0.82 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 0.89 (NS, CI not re-ported) per 1 SD increase ^1^

  EPA in serum                                         OR: 2.28 (1.14; 4.57) per 1 SD increase ^1^             OR: 0.89 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 0.63 (NS, CI not re-ported) per 1 SD increase ^1^

  DPA in serum                                         OR: 1.35 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 1.17 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 1.59 (NS, CI not re-ported) per 1 SD increase ^1^

  DHA in serum                                         OR: 1.53 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 1.02 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 1.06 (NS, CI not re-ported) per 1 SD increase ^1^

  LA in serum                                          OR: 0.66 (NS, CI not re-ported) per 1 SD increase ^1^   OR: 0.63 (0.46; 0.88) per 1 SD increase                 OR: 0.92 (NS, CI not re-ported) per 1 SD increase ^1^

  Yaemsiri et al. 2013 \[[@B32-nutrients-11-01467]\]                                                                                                                   

  No. of cases                                         96                                                      250                                                     209

  EPA in serum                                         OR: 0.51 (0.23; 1.14) per 1 SD increase ^2^             OR: 0.58 (0.36; 0.94) per 1 SD increase ^2^             OR: 0.84 (0.55; 1.30) per 1 SD increase ^2^

  DPA in serum                                         OR: 0.83 (0.47; 1.47) per 1 SD increase ^2^             OR: 0.64 (0.44; 0.94) per 1 SD increase ^2^             OR: 0.82 (0.55; 1.24) per 1 SD increase ^2^

  DHA in serum                                         OR: 0.70 (0.36; 1.36) per 1 SD increase ^2^             OR: 0.61 (0.40; 0.93) per 1 SD increase ^2^             OR: 0.66 (0.43; 1.02) per 1 SD increase ^2^

  Bork et al. 2018 \[[@B29-nutrients-11-01467]\]                                                                                                                       

  No. of cases                                         316                                                     835                                                     102

  ALA intake                                           HR Q2-5 vs. Q1:\                                        HR Q2-5 vs. Q1:\                                        HR Q2-5 vs. Q1:\
                                                       Q2: 1.03 (0.71; 1.51)\                                  Q2: 1.08 (0.84; 1.39)\                                  Q2: 1.30 (0.62; 2.72)\
                                                       Q3: 0.91 (0.62; 1.34)\                                  Q3: 1.23 (0.97; 1.56)\                                  Q3: 1.23 (0.59; 2.56)\
                                                       Q4: 0.90 (0.61; 1.34)\                                  Q4: 1.09 (0.84; 1.40)\                                  Q4: 1.08 (0.51; 2.29)\
                                                       Q5: 0.96 (0.65; 1.44)                                   Q5: 1.25 (0.98; 1.61)                                   Q5: 1.31 (0.63; 2.76)

  Bork et al. 2018 \[[@B33-nutrients-11-01467]\]                                                                                                                       

  No. of cases                                         297                                                     772                                                     99

  ALA in adipose tissue                                HR Q2-5 vs. Q1:\                                        HR Q2-5 vs. Q1:\                                        HR Q2-5 vs. Q1:\
                                                       Q2: 0.72 (0.48; 1.08)\                                  Q2: 1.00 (0.77; 1.31)\                                  Q2: 1.05 (0.53; 2.06)\
                                                       Q3: 0.63 (0.41; 0.96)\                                  Q3: 0.96 (0.73; 1.25)\                                  Q3: 1.16 (0.59; 2.27)\
                                                       Q4: 0.83 (0.56; 1.22)\                                  Q4: 1.02 (0.78; 1.33)\                                  Q4: 0.90 (0.43; 1.87)\
                                                       Q5: 0.95 (0.65; 1.40)                                   Q5: 1.05 (0.80; 1.38)                                   Q5: 1.91 (0.98; 3.70)

  Saber et al. 2017 \[[@B34-nutrients-11-01467]\]                                                                                                                      

  No. of cases                                         408                                                     256                                                     

  EPA in PL                                            HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        
                                                       Q2: 1.03 (0.70; 1.52)\                                  Q2: 1.10 (0.72; 1.66)\                                  
                                                       Q3: 0.97 (0.65; 1.44)\                                  Q3: 0.96 (0.62; 1.50)\                                  
                                                       Q4: 1.06 (0.71; 1.59)                                   Q4: 0.94 (0.61; 1.45)                                   

  DPA in PL                                            HR for Q2-4 vs. Q1:\                                    HR Q2-4 vs. Q1:\                                        
                                                       Q2: 1.05 (0.72; 1.53)\                                  Q2: 0.75 (0.50; 1.14)\                                  
                                                       Q3: 1.02 (0.69; 1.53)\                                  Q3: 0.83 (0.55; 1.35)\                                  
                                                       Q4: 0.98 (0.64; 1.53)                                   Q4: 0.59 (0.38; 0.93)                                   

  DHA in PL                                            HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        
                                                       Q2: 0.88 (0.60; 1.16)\                                  Q2: 1.25 (0.83; 1.90)\                                  
                                                       Q3: 0.72 (0.48; 1.07)\                                  Q3: 1.07 (0.69; 1.65)\                                  
                                                       Q4: 0.53 (0.34; 0.83)                                   Q4: 1.09 (0.69; 1.72)                                   

  Venø et al. 2019 \[[@B35-nutrients-11-01467]\]                                                                                                                       

  No. of cases in dietary analyses                     319                                                     844                                                     102

  No. of cases in AT analyses                          300                                                     781                                                     99

  Total LC n-3 intake                                  HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 0.97 (0.72; 1.30)\                                  Q2: 1.15 (0.94; 1.40)\                                  Q2: 1.36 (0.69; 2.66)\
                                                       Q3: 0.88 (0.65; 1.19)\                                  Q3: 1.20 (0.98; 1.45)\                                  Q3: 1.49 (0.78; 2.88)\
                                                       Q4: 0.69 (0.50; 0.95)                                   Q4: 1.06 (0.87: 1.30)                                   Q4: 2.50 (1.38; 4.53)

  Total LC n-3 in AT                                   HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 0.86 (0.61; 1.22)\                                  Q2: 0.91 (0.72; 1.15)\                                  Q2: 2.08 (1.04; 4.15)\
                                                       Q3: 1.09 (0.78; 1.52)\                                  Q3: 1.05 (0.83; 1.32)\                                  Q3: 2.04 (1.03; 4.04)\
                                                       Q4: 0.78 (0.53; 1.13)                                   Q4: 0.99 (0.79; 1.26)                                   Q4: 2.63 (1.33; 5.19)

  EPA intake                                           HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 0.86 (0.64; 1.16)\                                  Q2: 1.14 (0.94; 1.38)\                                  Q2: 1.17 (0.58; 2.35)\
                                                       Q3: 0.82 (0.60; 1.11)\                                  Q3: 1.16 (0.96; 1.41)\                                  Q3: 2.34 (1.27; 4.30)\
                                                       Q4: 0.66 (0.48; 0.91)                                   Q4: 1.05 (0.86; 1.28)                                   Q4: 2.02 (1.09; 3.73)

  EPA in AT                                            HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 0.96 (0.70; 1.32)\                                  Q2: 0.84 (0.68; 1.04)\                                  Q2: 1.13 (0.61; 2.11)\
                                                       Q3: 0.64 (0.43; 0.94)\                                  Q3: 0.61 (0.47; 0.79)\                                  Q3: 1.06 (0.52; 2.14)\
                                                       Q4: 0.52 (0.36; 0.76)                                   Q4: 0.69 (0.55; 0.88)                                   Q4: 1.52 (0.82; 2.81)

  DPA intake                                           HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 1.01 (0.74; 1.38)\                                  Q2: 1.27 (1.04; 1.55)\                                  Q2: 0.80 (0.41: 1.56)\
                                                       Q3: 0.91 (0.67; 1.25)\                                  Q3: 1.21 (0.99; 1.48)\                                  Q3: 1.14 (0.63; 2.08)\
                                                       Q4: 0.88 (0.64; 1.21)                                   Q4: 1.19 (0.98; 1.46)                                   Q4: 1.68 (0.96; 2.91)

  DPA in AT                                            HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 1.46 (1.04; 2.07)\                                  Q2: 1.37 (1.08; 1.74)\                                  Q2: 2.45 (1.19; 5.05)\
                                                       Q3: 1.23 (0.86; 1.76)\                                  Q3: 1.29 (1.01; 1.64)\                                  Q3: 2.61 (1.30; 5.25)\
                                                       Q4: 1.02 (0.69; 1.51)                                   Q4: 1.19 (0.93; 1.52)                                   Q4: 3.06 (1.50; 6.24)

  DHA intake                                           HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 0.90 (0.67; 1.22)\                                  Q2: 1.26 (1.04; 1.54)\                                  Q2: 0.97 (0.50; 1.89)\
                                                       Q3: 0.86 (0.63; 1.16)\                                  Q3: 1.17 (0.96; 1.43)\                                  Q3: 1.27 (0.68; 2.36)\
                                                       Q4: 0.72 (0.53; 0.99)                                   Q4: 1.13 (0.93; 1.38)                                   Q4: 2.12 (1.21; 3.69)

  DHA in AT                                            HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 0.94 (0.67; 1.32)\                                  Q2: 0.86 (0.68; 1.09)\                                  Q2: 1.37 (0.71; 2.64)\
                                                       Q3: 1.08 (0.77; 1.52)\                                  Q3: 1.07 (0.85; 1.34)\                                  Q3: 1.64 (0.87; 3.10)\
                                                       Q4: 0.79 (0.54; 1.16)                                   Q4: 0.92 (0.72; 1.17)                                   Q4: 2.00 (1.04; 3.84)

  Venø et al. 2017 \[[@B36-nutrients-11-01467]\]                                                                                                                       

  No. of cases                                         319                                                     844                                                     102

  LA intake                                            LA for SFA:\                                            LA for SFA:\                                            LA for SFA:\
                                                       HR: 0.84 (0.57; 1.25)\                                  HR: 0.96 (0.75; 1.23)\                                  HR: 1.46 (0.75; 2.85)\
                                                       LA for MUFA:\                                           LA for MUFA:\                                           LA for MUFA:\
                                                       HR: 1.05 (0.58; 1.90)\                                  HR: 0.67 (0.46; 0.96)\                                  HR: 1.35 (0.51; 3.55)\
                                                       LA for glycemic carbohydrates:\                         LA for glycemic carbohydrates:\                         LA for glycemic carbohydrates:\
                                                       HR: 0.96 (0.64; 1.44)                                   HR: 0.82 (0.64; 1.05)                                   HR: 1.55 (0.81; 3.00)

  Venø et al. 2018 \[[@B37-nutrients-11-01467]\]                                                                                                                       

  No. of cases                                         300                                                     781                                                     99

  LA in AT                                             HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\                                        HR Q2-4 vs. Q1:\
                                                       Q2: 0.72 (0.51; 1.01)\                                  Q2: 0.90 (0.72; 1.13)\                                  Q2: 1.28 (0.75; 2.19)\
                                                       Q3: 0.84 (0.61; 1.17)\                                  Q3: 0.87 (0.69; 1.03)\                                  Q3: 0.71 (0.37; 1.37)\
                                                       Q4: 0.61 (0.43; 0.88)                                   Q4: 0.87 (0.69; 1.11)                                   Q4: 0.86 (0.46; 1.59)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NS, Not statistically significant; AT, Adipose tissue. ^1^ Univariate analysis. ^2^ 99% Confidence interval. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. See [Table 1](#nutrients-11-01467-t001){ref-type="table"} and Tables 3--7 for study characteristics.

nutrients-11-01467-t003_Table 3

###### 

Characteristics of observational follow-up and nested case-control studies investigating biomarkers of alpha-linolenic acid (ALA) and total ischemic stroke.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and Study                                       Study Population, Design and Country                                           Sex   No. of Partici-pants and Cases         Baseline Age (yrs)   Biomarker                      Concentrations (%)   Follow-Up (yrs)   Measure of Association (95% CI)                           Variables Controlled for
  ------------------------------------------------------ ------------------------------------------------------------------------------ ----- -------------------------------------- -------------------- ------------------------------ -------------------- ----------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Iso et al. 2002 \[[@B31-nutrients-11-01467]\]          A Japanese cardiovascular risk survey population; Nested case-control; Japan   M+W   122 cases & 366 controls               40--85               ALA in serum                   Cases: 1.0%\         Not reported      OR: 0.86 (NS, CI not reported) per 1 SD increase in ALA   Univariate analysis. Matched by age; sex; community; year of serum storage; fasting status.
                                                                                                                                                                                                                                         Controls: 1.0%                                                                                   

  De Goede et al. 2013 \[[@B38-nutrients-11-01467]\]     The MORGEN Study cohort; Nested-case control; The Netherlands                  M+W   93 cases & 93 controls                 20--65               ALA in CE                      Cases: 0.53%\        10.5              OR: 1.02 (0.71; 1.46) for 1 SD increase in ALA            Age; gender; enrollment date; smoking; BMI; alcohol; high educational level; diabetes; hypertension; hypercholesterolemia.
                                                                                                                                                                                                                                         Controls: 0.52%                                                                                  

  Yamagishi et al. 2013 \[[@B39-nutrients-11-01467]\]    The Minneapolis field center of the ARIC cohort; Follow-up; United States      M+W   3870 subjects including 168 cases      45--65               ALA in PL and CE, separately   Mean:\               19.9              HR for Q4 vs. Q1:\                                        Age and sex. The authors stated that the point estimated did not materially change after additional adjustment for smoking status; cigarette-years and alcohol intake.
                                                                                                                                                                                                                                         CE: 0.4%\                              CE: 1.14 (0.76; 1.72)\                                    
                                                                                                                                                                                                                                         PL: 0.1%                               PL: 1.29 (0.82; 2.02)                                     

  Yaemsiri et al. 2013 \[[@B32-nutrients-11-01467]\]     The WHI-OS cohort; Nested case-control; United status                          W     964 cases & 964 controls               50--79               ALA in serum                   Cases: 0.53%\        Not reported      OR: 0.90 (0.74; 1.08) for 1 SD increase in ALA ^2^        Age; race; time of follow-up; BMI; smoking status; diabetes; aspirin use.
                                                                                                                                                                                                                                         Controls: 0.55%                                                                                  

  Fretts et al. 2014 \[[@B26-nutrients-11-01467]\]       The CHS cohort; Follow-up; United States                                       M+W   2709 subjects including 337 cases      ≥65                  ALA in PL                      Q1: 0.09%\           11.3 ^1^          Q2: 0.92 (0.65; 1.30)\                                    Age; sex; race; enrollment site; education; smoking status; diabetes; BMI; waist circumference; physical activity; alcohol; treated hypertension.
                                                                                                                                                                                                                                         Q3: 0.14%\                             Q3: 1.01 (0.72; 1.43)\                                    
                                                                                                                                                                                                                                         Q5: 0.22%                              Q4: 0.84 (0.59; 1.20)\                                    
                                                                                                                                                                                                                                                                                Q5: 0.97 (0.69; 1.36)                                     

  Daneshmand et al. 2016 \[[@B40-nutrients-11-01467]\]   The KIHD cohort; Follow-up; Finland                                            M     1828 subjects including 153 cases      42--60               ALA in serum                   Q1: \<0.58%\         21.2              Q2: 0.89 (0.58; 1.36)\                                    Age; examination year; BMI; smoking status; physical activity; alcohol.
                                                                                                                                                                                                                                         Q4: \>0.87%                            Q3: 0.63 (0.39; 1.02)\                                    
                                                                                                                                                                                                                                                                                Q4: 0.90 (0.58; 1.41)                                     

  Bork et al. 2018 \[[@B33-nutrients-11-01467]\]         The DCH cohort; Case-cohort; Denmark                                           M+W   54,648 subjects including 1735 cases   50--65               ALA in adipose tissue          Q1: 0.64%\           13.4              Q2: 0.95 (0.78; 1.16)\                                    Age; sex; duration of schooling; smoking; physical activity; waist circumference adjusted for BMI; alcohol.
                                                                                                                                                                                                                                         Q3: 0.84%\                             Q3: 0.86 (0.70; 1.06)\                                    
                                                                                                                                                                                                                                         Q5: 1.05%                              Q4: 0.93 (0.76; 1.14)\                                    
                                                                                                                                                                                                                                                                                Q5: 1.01 (0.82; 1.23)                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M, men; W, Women; OR, odds ratio; CI, Confidence interval; NS, not statistically significant; SD, standard deviation; MORGEN, The Monitoring Project on Risk Factors for Chronic Diseases; CE, Cholesterol ester; BMI, Body mass index; ARIC, Atherosclerosis Risk in Communities; PL, Plasma phospholipids; HR, Hazard ratio; Q, Quintile; CHS, Cardiovascular Health Study; KIHD, The Kuopio, Ischaemic Heart Disease Risk Factor Study; WHI-OS, The Women's Health Initiative Observational Follow-up Study; DCH, Diet, Cancer and Health. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise indicated. ^1^ Follow-up time was calculated as person-years of follow-up divided by the total number of participants; ^2^ 99% confidence interval.

nutrients-11-01467-t004_Table 4

###### 

Characteristics of observational follow-up studies investigating intake of LC n-3 PUFAs and total ischemic stroke.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and Study                                      Study Population Country                                              Sex     No. of Participants   Baseline Age (yrs)   Exposure Assessment                                          Intake (mg/d)    No. of Cases   Follow-up (yrs)   Hazard Ratios\           Variables Controlled for
                                                                                                                                                                                                                                                                                                (95% CI)                 
  ----------------------------------------------------- --------------------------------------------------------------------- ------- --------------------- -------------------- ------------------------------------------------------------ ---------------- -------------- ----------------- ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Iso et al. 2001 \[[@B30-nutrients-11-01467]\]         The NHS cohort;\                                                      W       79,839                34--59               FFQ                                                          EPA+DHA\         303            14                Q2: 0.83 (0.59; 1.18)\   Age; smoking status; time interval; joules; BMI; alcohol; menopausal status; post-menopausal hormone use; vigorous exercise; aspirin; multivitamins; hypertension; fruit; vegetables; SFA; trans unsaturated fat; linoleic acid; animal protein; calcium.
                                                        United States                                                                                                                                                                         Q1: 77\                                           Q3: 0.67 (0.47; 0.98)\   
                                                                                                                                                                                                                                              Q3: 171\                                          Q4: 0.82 (0.57; 1.18)\   
                                                                                                                                                                                                                                              Q5: 481                                           Q5: 0.71 (0.46; 1.10)    

  He et al. 2002 \[[@B41-nutrients-11-01467]\]          The HPFS cohort; United States                                        M       43,671                40--75               FFQ                                                          EPA+DHA\         377            12                Q2: 0.56 (0.35; 0.88)\   Age; smoking status; BMI; physical activity; hypertension; aspirin; fish oil; multivitamins; total calories; total fat; SFA; trans-unsaturated fat; alcohol; potassium; magnesium; fruit; vegetables; hypercholesterolemia.
                                                                                                                                                                                                                                              Q1: \<50\                                         Q3: 0.63 (0.40; 0.98)\   
                                                                                                                                                                                                                                              Q3: 200--400\                                     Q4: 0.54 (0.32; 0.91)\   
                                                                                                                                                                                                                                              Q5: ≥600                                          Q5: 0.73 (0.43; 1.25)    

  Yamagishi et al. 2008 \[[@B46-nutrients-11-01467]\]   The JACC cohort, Japan                                                M+W     57,972                40--79               FFQ                                                          Total LCn-3\     319            12.7              Q2: 1.06 (0.69; 1.63)\   Age; sex; hypertension; diabetes; smoking status; alcohol; BMI; mental stress; walking; sports; education levels; total energy; intake of cholesterol, SFA, n-6 PUFAs, vegetables; fruit.
                                                                                                                                                                                                                                              Q1: \<1180\                                       Q3: 1.31 (0.85; 2.01)\   
                                                                                                                                                                                                                                              Q5: ≥2110                                         Q4: 1.07 (0.68; 1.69)\   
                                                                                                                                                                                                                                                                                                Q5: 1.17 (0.71; 1.92)    

  Wallström et al. 2011 \[[@B45-nutrients-11-01467]\]   The Malmö Diet and Cancer cohort, Sweden                              M & W   M: 8083\              44--73               Combined FFQ, 7-day diet history and 1 hour diet interview   EPA+DHA\         M: 397\        13.5              M:\                      Age; diet assessment method version; total energy intake; season; BMI; smoking; education; alcohol; systolic blood pressure, anti-hypertensive treatment; anti-hyperlipidemic treatment; leisure time physical activity; dietary fiber.
                                                                                                                                      W: 12,402                                                                                               M:\              W: 346                           Q2: 1.36 (0.97; 1.89)\   
                                                                                                                                                                                                                                              Q1: 0.08% ^1^\                                    Q3: 1.29 (0.92; 1.80)\   
                                                                                                                                                                                                                                              Q3: 0.19% ^1^\                                    Q4: 1.12 (0.80; 1.57)\   
                                                                                                                                                                                                                                              Q5: 0.53% ^1^\                                    Q5: 1.12 (0.80; 1.57)\   
                                                                                                                                                                                                                                              W:\                                               W:\                      
                                                                                                                                                                                                                                              Q1: 0.07% ^1^\                                    Q2: 0.87 (0.60; 1.26)\   
                                                                                                                                                                                                                                              Q3: 0.18% ^1^\                                    Q3: 0.98 (0.68; 1.40)\   
                                                                                                                                                                                                                                              Q5: 0.49% ^1^                                     Q4: 0.98 (0.69; 1.41)\   
                                                                                                                                                                                                                                                                                                Q5: 1.04 (0.73; 1.48)    

  Montonen et al. 2009 \[[@B43-nutrients-11-01467]\]    The Finnish Mobile Clinic Health Examination Survey cohort, Finland   M+W     3958                  40--79               Dietary history interview                                    EPA+DHA\         364            28                Q2: 0.95 (0.71; 1.28\    Age; sex; energy intake; smoking; BMI; physical activity; geographic area; occupation; diabetes; post-hormonal hormone use; hypertension; S-cholesterol; intake of butter, vegetables, fruit and berries.
                                                                                                                                                                                                                                              Q1: 102\                                          Q3: 0.99 (0.74; 1.33)\   
                                                                                                                                                                                                                                              Q4: 655                                           Q4: 0.91 (0.66; 1.26)    

  Larsson et al. 2012 \[[@B28-nutrients-11-01467]\]     The Swedish Mammography cohort; Sweden                                W       34,670                49--83               FFQ                                                          EPA+DHA\         1310           10.4              Q2: 0.88 (0.74; 1.04)\   Age; smoking status and pack-years of smoking; education; BMI; physical activity; hypertension; diabetes; aspirin; family history of MI; intakes of alcohol, protein, fiber and cholesterol.
                                                                                                                                                                                                                                              Q1: 131\                                          Q3: 0.84 (0.70; 1.01)\   
                                                                                                                                                                                                                                              Q3: 289\                                          Q4: 0.83 (0.69; 0.99)\   
                                                                                                                                                                                                                                              Q5: 559                                           Q5: 0.83 (0.69; 0.99)    

  De Goede et al. 2012 \[[@B42-nutrients-11-01467]\]    The MORGEN Study cohort; The Netherlands                              M & W   M: 8,988W: 11,081     20--65               FFQ                                                          EPA+DHA\         M: 80\         10.5              M:\                      Age; smoking; BMI; educational level; parental history of MI; alcohol; total energy intake; intake of fiber, vitamin C, beta-carotene, SFAs, trans fatty acids, MUFAs, linoleic acid and ALA.
                                                                                                                                                                                                                                              M:\              W: 64                            Q2: 0.93 (0.50; 1.74)\   
                                                                                                                                                                                                                                              Q1: 44\                                           Q3: 0.87 (0.46; 1.65)\   
                                                                                                                                                                                                                                              Q4: 241\                                          Q4: 0.85 (0.45; 1.60)\   
                                                                                                                                                                                                                                              W:\                                               W:\                      
                                                                                                                                                                                                                                              Q1: 36\                                           Q2: 0.98 (0.50; 1.91)\   
                                                                                                                                                                                                                                              Q4: 225                                           Q3: 0.98 (0.50; 1.93)\   
                                                                                                                                                                                                                                                                                                Q4: 0.62 (0.29; 1.35)    

  Kippler et al. 2016 \[[@B44-nutrients-11-01467]\]     The Cohort of Swedish Men, Sweden                                     M       39,948                45--79               FFQ                                                          EPA+DHA\         2286           12                Q2: 1.02 (0.90; 1.16)\   Age; educational level; family history of MI; high cholesterol; hypertension; atrial fibrillation; aspirin; BMI; smoking status; alcohol; physical activity; fish oil supplements; energy intake; intake of fruit, vegetables, red and processed meat, dairy products, SFAs, MeHg and PCB.
                                                                                                                                                                                                                                              Q1:180\                                           Q3: 0.98 (0.85; 1.13)\   
                                                                                                                                                                                                                                              Q4: 730                                           Q4: 1.09 (0.94; 1.26)    

  Rhee et al. 2017 \[[@B27-nutrients-11-01467]\]        The WHS cohort; United States                                         W       38,392                ≥45                  FFQ                                                          EPA+DHA\         807            18.2 ^2^          Q2: 0.99 (0.80; 1.23)\   Age; randomized treatment assignment; BMI; smoking; alcohol; physical activity; oral conceptive use; HRT; multivitamin use; energy intake; family history of MI; hypertension; high cholesterol; diabetes.
                                                                                                                                                                                                                                              Q1: 0.06% ^1^\                                    Q3: 0.90 (0.72; 1.14)\   
                                                                                                                                                                                                                                              Q3: 0.16% ^1^\                                    Q4: 0.92 (0.74; 1.14)\   
                                                                                                                                                                                                                                              Q5: 0.40% ^1^                                     Q5: 1.04 (0.84; 1.29)    

  Venø et al. 2018 \[[@B35-nutrients-11-01467]\]        The DCH cohort; Denmark                                               M+W     55,338                50--65               FFQ                                                          Total LCn-3\     1879           13.5              Q2: 1.06 (0.93; 1.21)\   Age; sex; education; waist circumference adjusted by BMI; smoking; physical activity; alcohol; alcohol abstain.
                                                                                                                                                                                                                                              median: \~700                                     Q3: 1.06 (0.93; 1.21)\   
                                                                                                                                                                                                                                                                                                Q4: 1.06 (0.93; 1.20)    
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NHS, Nurses's Health Study; W, Women; FFQ, Food Frequency Questionnaire; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; Q, Quintile; CI, Confidence interval; BMI, Body mass index; SFA, Saturated fatty acids; M, men; HPFS, Health Professionals Follow-up Study; JACC, Japan Collaborative Cohort Study for Evaluation of Cancer Risk Study; LCn-3, Long-chain n-3 PUFAs; MI, Myocardial infarction; MORGEN, Monitoring Project on Risk Factors for Chronic Diseases; MUFA, Monounsaturated fatty acids; MeHg, Methylmercery; PCB, Polychlorinated biphenyls; WHS, Women's Health Study; DCH, Diet, Cancer and Health. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise indicated. ^1^ Percentage of total energy intake; ^2^ Follow-up time was calculated as person years divided by the total number of participants.
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###### 

Characteristics of observational follow-up and nested case-control studies investigating biomarkers of LC n-3 PUFAs and total ischemic stroke.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and Study                                        Study Population, Design and Country                                                                        Sex   No. of Partici-pants and Cases                                                               Baseline Age (yrs)   Biomarker                                            Concentrations\                                                              Follow-up\        Measure of Association (95% CI)                                                                                   Variables Controlled for
                                                                                                                                                                                                                                                                                                                                                   (%)                                                                          (yrs)                                                                                                                               
  ------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----- -------------------------------------------------------------------------------------------- -------------------- ---------------------------------------------------- ---------------------------------------------------------------------------- ----------------- ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Iso et al. 2002 \[[@B31-nutrients-11-01467]\]           A Japanese cardio-vascular risk survey population; Nested case-control; Japan                               M+W   122 cases & 366 controls                                                                     40--85               EPA, DPA and DHA in serum (separately)               EPA:\                                                                        Not reported      OR: 1.01 (NS, CI not reported) per 1 SD increase in EPA OR: 1.03 (NS, CI not reported) per 1 SD increase in DHA   Univariate analysis. Matched by age; sex; community; year of serum storage; fasting status.
                                                                                                                                                                                                                                                                                                                                                   Cases: 3.6\                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                   Controls: 3.7\                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                   DHA:\                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                   Cases: 4.5\                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                   Controls: 4.4                                                                                                                                                                                                    

  De Goede et al. 2013 \[[@B38-nutrients-11-01467]\]      The MORGEN Study cohort; Nested-case control; The Netherlands                                               M+W   93 cases & 93 controls                                                                       20--65               EPA+DHA in CE                                        Cases: 1.57\                                                                 10.5              OR: 1.33 (0.96; 1.84) for 1 SD increase in EPA+DHA                                                                Age; gender; enrollment date; smoking; BMI; alcohol; high educational level; diabetes; hypertension; hypercholesterolemia.
                                                                                                                                                                                                                                                                                                                                                   Controls: 1.25                                                                                                                                                                                                   

  Mozaffarian et al. 2013 \[[@B48-nutrients-11-01467]\]   The CHS cohort; Follow-up; United States                                                                    M+W   2692 subjects including 319 cases                                                            ≥65                  Total LCn-3, EPA, DPA and DHA in PL                  Total LCn-3\                                                                 11.5 ^1^          Q2: 0.88 (0.63; 1.23)\                                                                                            Age; sex; race; enrollment site; fatty acid measurement batch; education; smoking status; diabetes; atrial fibrillation; treated hypertension; leisure time physical activity; BMI; waist circumference; alcohol; intake of broiled and baked fish, fried fish, red meat, fruits, vegetables and fiber.
                                                                                                                                                                                                                                                                                                                                                   Q1: 3.17\                                                                                      Q3: 0.77 (0.54; 1.08)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                   Q3: 4.21\                                                                                      Q4: 0.93 (0.66; 1.31)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                   Q5: 6.04                                                                                       Q5: 0.63 (0.43; 0.94)                                                                                             

  Yaemsiri et al. 2013 \[[@B32-nutrients-11-01467]\]      The WHI-OS cohort; Nested case-control; United status                                                       W     964 cases & 964 controls                                                                     50--79               EPA, DPA and DHA in serum (separately)               EPA:\                                                                        Not reported      OR: 0.84 (0.70; 1.01) for 1 SD increase in EPA ^2^\                                                               Age; race; time of follow-up; BMI; smoking status; diabetes; aspirin.
                                                                                                                                                                                                                                                                                                                                                   Cases: 0.56\                                                                                   OR: 0.72 (0.59; 0.87) for 1 SD increase in DHA ^2^                                                                
                                                                                                                                                                                                                                                                                                                                                   Controls: 0.60\                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                   DHA:\                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                   Cases: 1.75\                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                   Controls: 1.97                                                                                                                                                                                                   

  Yamagishi et al. 2013 \[[@B39-nutrients-11-01467]\]     The Minneapolis field center of the ARIC cohort; Follow-up; United States                                   M+W   3870 subjects including 168 cases                                                            45--65               Total LCn-3, EPA and DHA in PL and CE (separately)   Total LCn-3\                                                                 19.9              HR for Q4 vs. Q1:\                                                                                                Age and sex. The authors stated that the point estimated did not materially change after additional adjustment for smoking status; cigarette-years and alcohol intake.
                                                                                                                                                                                                                                                                                                                                                   CE:\                                                                                           CE: 1.16 (0.75; 1.79)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                   Q1: 0.22--0.77\                                                                                PL: 0.86 (0.56; 1.32)                                                                                             
                                                                                                                                                                                                                                                                                                                                                   Q4: 1.15--6.02\                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                   PL:\                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                   Q1: 1.51--3.57\                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                   Q4: 4.75--13.5                                                                                                                                                                                                   

  Daneshmand et al. 2016 \[[@B40-nutrients-11-01467]\]    The KIHD cohort; Follow-up; Finland                                                                         M     1828 subjects including 153 cases                                                            42--60               Total LCn-3, EPA, DPA and DHA in serum               Total LCn-3\                                                                 21.2              Q2: 0.66 (0.41; 1.07)\                                                                                            Age; examination year; BMI; smoking status; physical activity; alcohol.
                                                                                                                                                                                                                                                                                                                                                   Q1: \<3.63%\                                                                                   Q3: 0.91 (0.58; 1.42)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                   Q4: \>5.34%                                                                                    Q4: 0.98 (0.64; 1.51)                                                                                             

  Saber et al. 2017 \[[@B34-nutrients-11-01467]\]         Pooled analysis of the NHS and HFPS (nested case-control), and the CHS (follow-up) cohorts, United States   M+W   A total of 953 cases and 437 controls from the NHS and HFPS and 3941 subjects from the CHS   NHS:\                EPA, DPA and DHA in PL (separately)                  Cohort-specific fatty acid content in quartiles can be found in the paper.   NHS+HPFS: 11.2\   EPA:\                                                                                                             Age; race; sex; smoking status; physical activity; alcohol; hypertension; family history of diabetes; parental history of CVD; menopausal status; postmenopausal hormone use; BMI; aspirin; intake of processed and unprocessed meat, fruits and vegetables.
                                                                                                                                                                                                                                                                         30--55\                                                                                                                                                CHS: 8.3          Q2: 0.95 (0.77; 1.18)\                                                                                            
                                                                                                                                                                                                                                                                         HFPS:\                                                                                                                                                                   Q3: 0.93 (0.74; 1.16)\                                                                                            
                                                                                                                                                                                                                                                                         40--75\                                                                                                                                                                  Q4: 0.94 (0.77; 1.19)\                                                                                            
                                                                                                                                                                                                                                                                         CHS:\                                                                                                                                                                    DHA:\                                                                                                             
                                                                                                                                                                                                                                                                         ≥65                                                                                                                                                                      Q2: 0.93 (0.75; 1.14)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                  Q3: 0.85 (0.71; 1.10)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                  Q4: 0.80 (0.63; 1.00)                                                                                             

  Venø et al. 2019 \[[@B35-nutrients-11-01467]\]          The DCH cohort; Case-cohort, Denmark                                                                        M+W   55,338 subjects including 1755 cases                                                         50--65               Total LCn-3, EPA, DPA and DPA in adipose tissue      Total LCn-3:\                                                                13.5              Q2: 0.98 (0.82; 1.17)\                                                                                            Age; sex; education; waist circumference adjusted for BMI; smoking; physical activity; alcohol and alcohol abstain.
                                                                                                                                                                                                                                                                                                                                                   Q1: 0.42\                                                                                      Q3: 1.12 (0.94; 1.33)\                                                                                            
                                                                                                                                                                                                                                                                                                                                                   Q4: 0.94                                                                                       Q4: 1.08 (0.90; 1.30)                                                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M, men; W, Women; EPA, Eicosapentaenoic acid; DPA, Docosapentaenoic acid; DHA, Docosahexaenoic acid; OR, Odds ratio; CI, Confidence interval; NS, Not statistically significant; SD, Standard deviation; MORGEN, The Monitoring Project on Risk Factors for Chronic Diseases; CE, Cholesterol esters; BMI, Body mass index; CHS, Cardiovascular Health Study; LC n-3, Long-chain n-3 PUFAs, PL, Plasma phospholipids; Q, Quintile; WHI-OS, Women's Health Initiative Observational Follow-up Study; KIHD, The Kuopio, Ischaemic Heart Disease Risk Factor Study; NHS, Nurses' Health Study; HPFS, Health Professionals Follow-up Study; DCH, Diet, Cancer and Health. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise indicated. ^1^ Follow-up time was calculated as person years divided by the total number of participants; ^2^ 99% confidence interval.
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###### 

Characteristics of observational follow-up studies investigating intake of linoleic acid (LA) and total ischemic stroke.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and Study                                      Study Population and Country               Sex     No. of Participants   Baseline Age (yrs)   Exposure Assessment                                       Intake (g/d)    No. of Cases   Follow-up (yrs)   Hazard Ratios\                    Variables Controlled for
                                                                                                                                                                                                                                                                 (95% CI)                          
  ----------------------------------------------------- ------------------------------------------ ------- --------------------- -------------------- --------------------------------------------------------- --------------- -------------- ----------------- --------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Larsson et al. 2012 \[[@B28-nutrients-11-01467]\]     The Swedish Mammography Cohort, Sweden     W       34,670                49--83               FFQ                                                       LA+AA\          1310           10.4              Q2: 0.98 (0.84; 1.16)\            Age; smoking status and pack-years of smoking; education; BMI; physical activity; hypertension; diabetes; aspirin; family history of MI; intakes of alcohol, protein, fiber and cholesterol.
                                                                                                                                                                                                                Q1: 4.7\                                         Q3: 0.96 (0.81; 1.14)\            
                                                                                                                                                                                                                Q3: 6.0\                                         Q4: 1.02 (0.85; 1.21)\            
                                                                                                                                                                                                                Q5: 8.0                                          Q5: 0.96 (0.80; 1.15)             

  Wallstrøm et al. 2012 \[[@B45-nutrients-11-01467]\]   The Malmö Diet and Cancer cohort, Sweden   M & W   M: 8083\              44--73               Combined FFQ, 7-day diet history and 1 h diet interview   LA+AA:\         M: 397W: 346   13.5              M:\                               Age; diet assessment method version; total energy intake; season; BMI; smoking; education; alcohol; systolic blood pressure, anti-hypertensive treatment; anti-hyperlipidemic treatment; leisure time physical activity; dietary fiber.
                                                                                                           W: 12,402                                                                                            Q1: 3.5% ^1^\                                    Q2: 1.12 (0.82; 1.52)\            
                                                                                                                                                                                                                Q3: 5.0% ^1^\                                    Q3: 1.02 (0.74; 1.39)\            
                                                                                                                                                                                                                Q5: 7.1% ^1^\                                    Q4: 1.10 (0.80; 1.50)\            
                                                                                                                                                                                                                W:\                                              Q5: 1.16 (0.84; 1.58)\            
                                                                                                                                                                                                                Q1: 3.3% ^1^\                                    W:\                               
                                                                                                                                                                                                                Q3: 4.7% ^1^\                                    Q2: 0.99 (0.72; 1.36)\            
                                                                                                                                                                                                                Q5: 6.7% ^1^                                     Q3: 0.86 (0.62; 1.19)\            
                                                                                                                                                                                                                                                                 Q4: 1.02 (0.73; 1.41)\            
                                                                                                                                                                                                                                                                 Q5: 0.81 (0.57; 1.14)             

  Venø et al. 2017 \[[@B36-nutrients-11-01467]\]        The DCH cohort; Denmark                    M+W     55,338                50--65               FFQ                                                       Median 10.7     1879           13.5              LA for SFA:\                      Age; sex; total energy intake; education status; physical activity; waist circumference adjusted for BMI; alcohol; alcohol abstain; smoking.
                                                                                                                                                                                                                                                                 0.98 (0.83; 1.16)\                
                                                                                                                                                                                                                                                                 LA for MUFA\                      
                                                                                                                                                                                                                                                                 0.80 (0.63; 1.02)\                
                                                                                                                                                                                                                                                                 LA for glycemic carbohydrates:\   
                                                                                                                                                                                                                                                                 0.92 (0.78; 1.09)                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M, men; W, Women; FFQ, Food Frequency Questionnaire; AA, Arachidonic acid; Q, Quintile; CI, Confidence interval; BMI, Body mass index; MI, Myocardial infarction; SFA, Saturated fatty acids; MUFA, Monounsaturated fatty acids; DCH, Diet Cancer and Health. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise indicated. ^1^ Percentage of total energy intake.
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###### 

Characteristics of observational follow-up and nested case-control studies investigating biomarkers of linoleic acid (LA) and total ischemic stroke.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author and Study                                       Study Population, Design and Country                                           Sex   No. of Partici-pants and Cases                         Baseline Age (yrs)   Biomarker                      Concentrations (%)   Follow-up (yrs)   Measure of Association (95% CI)                     Variables Controlled for
  ------------------------------------------------------ ------------------------------------------------------------------------------ ----- ------------------------------------------------------ -------------------- ------------------------------ -------------------- ----------------- --------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Iso et al. 2002 \[[@B31-nutrients-11-01467]\]          A Japanese cardiovascular risk survey population; Nested case-control; Japan   M+W   122 cases & 366 controls                               40--85               LA in serum                    Cases: 26.1%\        Not reported      OR 0.66 (0.49; 0.88) per 1 SD increase in LA        Age; sex; community; year of serum storage; fasting status; BMI; cigarette smoking status; alcohol; hypertension; serum cholesterol levels, triglyceride and glucose levels.
                                                                                                                                                                                                                                                         Controls: 27.9%                                                                            

  Yaemsiri et al. 2013 \[[@B32-nutrients-11-01467]\]     The WHI-OS cohort; Nested case-control; United status                          W     964 cases &964 controls                                50--79               LA in serum                    Cases: 26.7%\        Not reported      OR: 0.92 (0.79; 1.08) for 1 SD increase in LA ^2^   Age; race; time of follow-up; BMI; smoking status; diabetes; aspirin.
                                                                                                                                                                                                                                                         Controls: 27.1%                                                                            

  Yamagishi et al. 2013 \[[@B39-nutrients-11-01467]\]    The Minneapolis field center of the ARIC cohort; Follow-up; United States      M+W   3870 subjects including 168 cases                      45--65               LA in PL and CE (separately)   CE:\                 19.9              HR for Q4 vs. Q1:\                                  Age and sex. The authors stated that the point estimated did not materially change after additional adjustment for smoking status; cigarette-years and alcohol intake.
                                                                                                                                                                                                                                                         Q1: 21.5--51.3%\                       CE: 0.64 (0.43; 0.97)\                              
                                                                                                                                                                                                                                                         Q4: 57.4--68.2%\                       PL: 0.69 (0.45; 1.05)                               
                                                                                                                                                                                                                                                         PL:\                                                                                       
                                                                                                                                                                                                                                                         Q1: 9.0--20.3%\                                                                            
                                                                                                                                                                                                                                                         Q4: 23.7--32.4%                                                                            

  De Goede et al. 2013 \[[@B38-nutrients-11-01467]\]     The MORGEN Study cohort; Nested-case control; The Netherlands                  M+W   93 cases & 93 controls                                 20--65               LA in CE                       Cases: 54.2%\        10.5              OR: 0.81 (0.54; 1.24) for 1 SD increase in LA       Age; gender; enrollment date; smoking; BMI; alcohol; high educational level; diabetes; hypertension; hypercholesterolemia.
                                                                                                                                                                                                                                                         Controls: 55.4%                                                                            

  Wu et al. 2014 \[[@B49-nutrients-11-01467]\]           The CHS cohort, Follow-up, United States                                       M+W   2792 subjects including 362 cases                      ≥65                  LA in PL                       Q1: 16.6%\           12.3 ^1^          Q2: 1.00 (0.71; 1.40)\                              Age; sex; race; enrollment site; education; smoking status; diabetes; atrial fibrillation; hypertension; leisure-time physical activity; BMI; waist circumference; alcohol; plasma LC n-3 PUFAs.
                                                                                                                                                                                                                                                         Q3: 19.7%\                             Q3: 0.90 (0.64; 1.27)\                              
                                                                                                                                                                                                                                                         Q5: 22.9%                              Q4: 0.88 (0.62; 1.26)\                              
                                                                                                                                                                                                                                                                                                Q5: 0.88 (0.61; 1.27)                               

  Daneshmand et al. 2016 \[[@B40-nutrients-11-01467]\]   The KIHD cohort; Follow-up; Finland                                            M     1828 subjects including 153 cases                      42--60               LA in serum                    Q1: \<23.7%\         21.2              Q2: 0.72 (0.46; 1.14)\                              Age; examination year; BMI; smoking status; physical activity; alcohol.
                                                                                                                                                                                                                                                         Q4: \>29.5%                            Q3: 0.87 (0.55; 1.37)\                              
                                                                                                                                                                                                                                                                                                Q4: 1.07 (0.68; 1.67)                               

  Venø et al. 2018 \[[@B37-nutrients-11-01467]\]         The DCH cohort, Case-cohort, Denmark                                           M+W   55,338 subjects including 1755 cases                   50--65               LA in adipose tissue           Q1: \<9.6%\          13.5              Q2: 0.92 (0.77; 1.09)\                              Age; sex; alcohol; alcohol abstain; waist circumference adjusted for BMI; education status; smoking; physical activity.
                                                                                                                                                                                                                                                         Q4: \>11.7%                            Q3: 0.85 (0.71; 1.02)\                              
                                                                                                                                                                                                                                                                                                Q4: 0.78 (0.65; 0.93)                               

  Marklund et al. 2019 \[[@B23-nutrients-11-01467]\]     FORCE Consortium; Individual pooled analysis of cohort studies Multinational   M+W   The FORCE Consortium population including 3705 cases   49--77               LA in PL, TP; CE, & AT         PL: 6.9%\            2.5--31.9         HR per IQR:\                                        Age; sex; race; field center; BMI; education; smoking; physical activity; alcohol; diabetes; treated hypertension; treated hypercholesterolemia; aspirin; levels of ALA, EPA and trans isomers of oleic acid and trans isomers of linoleic acid.
                                                                                                                                                                                                                                                         TP: 11.4%\                             PL: 0.95 (0.82; 1.10)\                              
                                                                                                                                                                                                                                                         CE: 11.9%\                             TP: 0.84 (0.66; 1.06)\                              
                                                                                                                                                                                                                                                         RBC: 4.9%\                             CE: 0.67 (0.51; 0.88)\                              
                                                                                                                                                                                                                                                         AT: 6.2%                               AT: 0.87 (0.65; 1.15)\                              
                                                                                                                                                                                                                                                                                                Overall: 0.88 (0.79; 0.98)                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: M, men; W, Women; OR, odds ratio; SD, standard deviation; BMI, Body mass index; WHI-OS, Women's Health Initiative Observational Follow-up Study; ARIC, Atherosclerosis Risk in Communities; CE, Cholesterol ester; PL, Phospholipids; HR, Hazard ratio; CI, Confidence interval; Q, Quintile; MORGEN, Monitoring Project on Risk Factors for Chronic Diseases; CHS, Cardiovascular Health Study; LC n-3, Long-chain n-3 polyunsaturated fatty acids; KIHD, Kuopio, Ischaemic Heart Disease Risk Factor Study; DCH, Diet, Cancer and Health; FORCE, Fatty Acid and Outcomes Research Consortium; TP, Total plasma; AT, Adipose tissue; ALA, alpha-linolenic acid; EPA, Eicosapentanoic acid. The presented measures of association was selected for models that included adjustment for lifestyle factors without including dietary covariates whenever possible. The lowest group of exposure was used as reference unless otherwise indicated. ^1^ Follow-up time was calculated as person-years of follow-up divided by the total number of participants; ^2^ 99% confidence interval.
